Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Updated Pfizer-BioNTech and Moderna bivalent boosters contain spike proteins from the original and BA.4 and BA.5 omicron variants.
The engineered protein vaccine was highly effective in a clinical trial but faced a long delay for authorization.
Remdesivir (Veklury) is now approved for kids ages 28 days to 12 years.
Immunocompromised people ages 12 and older are also eligible for an additional shot.
Molnupiravir is authorized for people at high risk for severe COVID-19 when other treatment options are not available.
Paxlovid, which reduces the risk of hospitalization or death by about 90%, is expected to be a game-changer.
Molnupiravir, the first oral antiviral for COVID-19, reduces the risk of hospitalization or death if started within five days.
Robert Califf headed the Food and Drug Administration for 10 months under Obama. Will he manage to implement his ideas this time around?
Vaccine effectiveness for children ages 5 to 11 was 91%, and serious side effects are rare.
As schools reopen, parents have questions about when COVID-19 vaccines will be available for children under 12.
Full approval could encourage more people to get vaccinated and raises the prospect of off-label use.
The booster is recommended for organ transplant recipients, people receiving cancer treatment and people with advanced or untreated HIV.
Three decades ago, HIV advocates helped lay the groundwork for the response to COVID-19.
The Pfizer-BioNTech vaccine was 100% effective in a study of adolescents; trials for younger children are now underway.
The Johnson & Johnson vaccine, which is easier to store and deliver, will help speed up the coronavirus vaccine rollout.
Bamlanivimab and etesevimab may be given to people with mild to moderate COVID-19 who are at high risk for progression to severe disease.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.